Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06972212




Registration number
NCT06972212
Ethics application status
Date submitted
6/05/2025
Date registered
14/05/2025
Date last updated
3/07/2025

Titles & IDs
Public title
Pharmacodynamic Study of 100mg Suzegtrigine vs Placebo in Healthy Male Adults
Scientific title
A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Pharmacodynamic Effects of Suzetrigine in Healthy Male Adults
Secondary ID [1] 0 0
LTG-OBS-103
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pain Detection 0 0
Pain Threshold 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - suzetrigine 100mg
Other interventions - Placebo

Other: Schedule A - participants receive suzetrigine 100mg in treatment period 1, and receive placebo in treatment period 2

Other: Schedule B - participants receive placebo in treatment period 1, and receive suzetrigine 100mg in treatment period 2


Treatment: Drugs: suzetrigine 100mg
Suzetrigine is an inhibitor of the NaV1.8 voltage-gated sodium channel and FDA approved for the treatment of moderate-to-severe acute pain in adults

Other interventions: Placebo
biologically inactive placebo comparator
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline pain score after dosing with suzetrigine vs. placebo
Timepoint [1] 0 0
0-24 hours during each treatment period
Primary outcome [2] 0 0
Time to reach Pain Detection Threshold (PDT) and Pain Tolerance Threshold (PTT) after dosing with suzetrigine vs placebo
Timepoint [2] 0 0
0-24 hours during each treatment period

Eligibility
Key inclusion criteria
1. Male participants aged 18 to 55 years, inclusive, at the time of signing the informed consent.
2. Overtly healthy with no clinically relevant abnormalities based on the medical history, physical examinations, clinical laboratory evaluations, and 12-lead ECG that, in the opinion of the investigator, would affect participant safety.
3. Body mass index (BMI) within the range of 18-32 kg/m2 (inclusive).
4. Male participants are eligible to participate if they agree to refrain from donating semen. Plus, agree to use a male condom when having sexual intercourse with woman of childbearing potential or women who are currently pregnant.
5. Capable of giving signed informed consent.
6. Willing to undergo Pain Tolerability Assessments using the cold pressor procedure.
Minimum age
18 Years
Maximum age
55 Years
Sex
Males
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Inability to take oral medications or gastrointestinal abnormalities potentially impacting absorption.
2. Clinically significant cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, gastrointestinal, immunological, dermatological, neurological, or psychiatric disease which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the investigator, unacceptably increase the participant's risk by participating in the study.
3. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST), >1.5 x upper limit of normal (ULN) at Screening.
4. Total bilirubin > 1.5 x ULN (for participants with known Gilbert's syndrome, a total bilirubin >1.5 x ULN is allowed provided the direct bilirubin is =1.5 x ULN)) at Screening.
5. Estimated glomerular filtration rate (eGFR) <80 mL/min based on serum creatinine levels using the 2021 chronic kidney disease epidemiology (CKD-EPI) creatinine equation at Screening. The CKD-EPI 2009 equation may be used per site standard practice.
6. Creatinine phosphokinase is = 2 × ULN at Screening.
7. Any of the protocol defined abnormalities on 12-lead ECG or blood pressure (BP) at Screening, confirmed by repeat.
8. Use of prescription drugs = 14 days (or 5 half-lives of the drug, whichever is longer) prior to Day 1, use of over-the-counter drugs, herbal medications, or vitamin supplements = 7 days (or 5 half-lives of the drug, whichever is longer) prior to Day 1 or use of antibiotics and systemic steroids = 28 days prior Day 1. The Sponsor may allow exceptions only if the medication's administration is deemed unlikely to confound safety or efficacy.
9. Any vaccination = 14 days prior to Day 1 or anticipated vaccination while participating in the study.
10. Receipt of an investigational product or device, or participation in a drug research study = 28 days (or 5 half-lives of the drug, whichever is longer) prior to Day 1.
11. Receipt of an investigational biologic / monoclonal antibody within 180 days (or 5 half-lives, whichever is longer) prior to Day 1.
12. Positive for Coronavirus Disease 2019 (COVID-19) suggesting active infection at Screening or on Day 1.
13. Positive human immunodeficiency virus (HIV) at Screening.
14. Presence of any condition for which administration of a sodium channel blocker is contraindicated.
15. Smoking or vaping of tobacco or nicotine, or any other use of tobacco or any products containing nicotine = 14 days prior to Day 1.
16. Consumption of alcohol within 48 hours prior to Day 1 and/or food and beverages containing methylxanthines (caffeinated coffee, caffeinated tea, caffeinated soda, and chocolate) within 48 hours of Day 1, and grapefruit, grapefruit juice, Seville oranges, or Seville orange juice = 14 days prior to Day 1.
17. Positive urine drug screen, urine cotinine test, or alcohol breath test at Screening or on Day 1.
18. Past or current history or evidence of alcohol abuse, regular use of more than 2 units of alcohol per day (1 unit of alcohol = 150 mL of wine, 360 mL of beer, or 45 mL of alcohol 40%), use of any illicit drugs (such as cocaine, phencyclidine [PCP], and crack) within 6 months of Screening, and/or a positive screen for substances of abuse or alcohol at Screening or on Day 1.
19. Past or current history or evidence of dependence on recreational drug use (eg, marijuana), use of recreational drugs = 28 days prior to Day 1, or positive test result at Screening or on Day 1.
20. Donation or loss of over 500 mL blood = 3 months prior to Day 1.
21. Use of moderate or strong CYP 3A4 inhibitors or inducers.
22. Has known psychiatric disorders that would interfere with the cooperation with the requirements of the study.
23. Participant is under legal custodianship.
24. Pain conditions that may require analgesic treatment during the study or history of opioid medication use
25. Hand/arm/skin conditions impacting ability to participate in cold pressor assessment.
26. Recent serious injury, surgical procedure, or medical condition which, in the opinion of the investigator, unacceptably increases the participant's risk by being included in the study.
27. Meets protocol defined Pain Tolerance Threshold (PTT) in any of the 5 predose cold pressor tests
28. Any relative or absolute contraindication to suzetrigine as outlined in the prescribing information for Journavx.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 0
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
4/06/2025
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
28/06/2025
Sample size
Target
Accrual to date
Final
20
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Latigo Biotherapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Cheif Medical Officer
Address 0 0
Country 0 0
Phone 0 0
626-862-7778
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06972212